Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors

García-Sánchez, Javier; Mafla-España, Mayra Alejandra; Torregrosa, María Dolores; Cauli, Omar

doi:10.3390/biomedicines10071634

Cited by 7 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the premise is raised that the inhibition of aromatase activity in patients could trigger an increase in androstenedione production. The results of a longitudinal study, carried out in patients with breast cancer undergoing hormonal treatment with aromatase inhibitors, support this idea [23]. There was a significant increase in the plasma levels of androstenedione due to the inhibition of aromatase activity, which highlights the importance of this enzyme in the regulation of hormone synthesis.…”

Section: Discussionmentioning

confidence: 82%

“…At the time of the study, 63% of the patients had undergone a prostatectomy, and 37% had not. The mean BMI of the participants was 27.7 ± 0.42 (SEM; range: [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38], and according to these data, 23.1% of the patients had a normal weight (BMI = 18.5-24.9 kg/m 2 ), 55.4% were overweight (BMI = 25-29.9 kg/m 2 ), and 21.5% were obese (BMI > 30 kg/m 2 ). None of the patients were underweight (BMI < 18.5 kg/m 2 ).…”

Section: Sociodemographic and Clinical Datamentioning

confidence: 99%

“…Moreover, the possible involvement of other androgens, such as androstenedione and dehydroepiandrosterone (DHEA), in frailty syndrome has not yet been studied in men with PCa. To date, only one long-term study performed in postmenopausal women with oestrogen receptor-positive breast cancer being treated with aromatase inhibitors has found a significant association between elevated androstenedione levels and the progression of frailty syndrome [23]. Our group previously published [24] that the presence of metastatic disease in PCa during castration-sensitive therapy with LHRH analogues is not accompanied by a general worse frailty status, e.g., the number of frailty criteria was comparable with men with localised disease under ADT to prevent cancer relapse.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy

Mafla-España,

Torregrosa,

Beamud-Cortés

et al. 2023

Biomolecules

Self Cite

View full text Add to dashboard Cite

Background: Androgen deprivation therapy (ADT) is a mainstay of prostate cancer in both adjuvant and palliative settings. Since androgens are crucial for functional status and psychological functions, we evaluated whether blood testosterone, androstenedione, or DHEA concentrations were associated with functional status and psychological alterations in patients with localised (PCa) or metastatic prostate cancer (mPCa) receiving ADT with analogues of luteinising hormone-releasing hormone (LHRH). Methods: The five Fried criteria were considered to identify frailty syndrome. In addition, complementary evaluations were carried out to measure other variables of interest. Sleep quality was assessed using the Athens Insomnia Scale, cognitive functions were assessed using the Mini-Mental State Examination, and symptoms of depression were measured using the Yesavage Geriatric Depression Scale. Logistic regression analysis was performed to determine if the androgens level could be related to frailty syndrome, sleep impairment, depressive symptoms, and cognitive functions. Results: The results of the multivariate analyses show that high concentrations of androstenedione were significantly associated with frailty syndrome in both groups (p = 0.018; odds ratio = 4.66, 95% confidence interval [1.30–16.6]). There were significant relationships between frailty syndrome and the systemic concentration of androstenedione (p = 0.01), but not the concentration of testosterone (p = 0.60) or DHEA (p = 0.42). In addition, the results of the non-parametric tests show significant results between a decreased gait speed in the two groups (metastatic and localised) and the concentration of androstenedione (p = 0.015). High androstenedione levels were associated with a slow walking speed in the mCaP group (p = 0.016), while high testosterone levels were associated with a better walking speed in the localised CaP group (p = 0.03). For the concentration of androstenedione in plasma, the area under the curve was 0.72, with a 95% CI of 0.55–0.88 with acceptable values, and with a cut-off point of 4.51 pg/mL, a sensitivity of 82.9%, and specificity of 53.8%. No relationships between the concentration of androgens in plasma and sleep quality, cognitive functions, or symptoms of depression suggest that the changes were specific to frailty syndrome. Conclusions: Further research into the role of androstenedione should be evaluated in follow-up studies in order to recommend its use as a suitable biomarker of frailty syndrome in prostate cancer patients.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Sociodemographic and Clinical Datamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy

Mafla-España,

Torregrosa,

Beamud-Cortés

et al. 2023

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, other studies have also found significant correlations between androstenedione and other diseases. For example, Javier et al 33 found that androstenedione can predict the progression of Frailty Syndrome in patients with localized breast cancer treated with aromatase inhibitors. Adriaansen et al 34 reported that diurnal salivary androstenedione levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia.…”

Section: Discussionmentioning

confidence: 99%

Metabolomics Identifies and Validates Serum Androstenedione as Novel Biomarker for Diagnosing Primary Angle Closure Glaucoma and Predicting the Visual Field Progression

Ren

Qiu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness worldwide, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines. A growing body of evidence shows metabolic alterations in patients with glaucoma. we aimed to develop and validate potential metabolite biomarkers to diagnose and predict the visual field progression of PACG. Methods: Here, we used a 5-phases (discovery phase, validation phase 1, validation phase 2, supplementary phase, and cohort phase) multicenter (EENT hospital, Shanghai Xuhui central hospital), cross-sectional, prospective cohort study design to perform widely-targeted metabolomics and chemiluminescence immunoassay to determine candidate biomarkers. Five machine learning (random forest, support vector machine, lasso, K-Nearest neighbor, and Gaussian NB) approaches were used to identify an optimal algorithm. The discrimination ability was evaluated using the area under the receiver operating characteristic curve (AUC). Calibration was assessed by Hosmer-Lemeshow tests and calibration plots. Results: Studied serum samples were collected from 616 participants, and 1464 metabolites were identified. Machine learning algorithm determines that androstenedione exhibited excellent discrimination and acceptable calibration in discriminating PACG across the discovery phase (discovery set 1, areas under the receiver operating characteristic curve [AUC] =1.0 [95%CI, 1.00-1.00]; discovery set, AUC=0.85 [95%CI, 0.80-0.90]) and validation phases (internal validation, AUC=0.86 [95%CI, 0.81-0.91]; external validation, AUC=0.87 [95%CI, 0.80-0.95]). Androstenedione also exhibited a higher AUC (0.92-0.98) to discriminate the severity of PACG. In the supplemental phase, serum androstenedione levels were consistent with those in aqueous humor (r=0.82, P=0.038) and significantly (P=0.021) decreased after treatment. Further, cohort phase demonstrates that higher baseline androstenedione levels (hazard ratio=2.71 [95% CI: 1.199-6.104], P=0.017) were associated with faster visual field progression. Conclusion: Our study demonstrates serum androstenedione as a novel biomarker that can be used to diagnose PACG and predict visual field progression.

show abstract

“…Preclinical research reveals valuable information on human diseases by employing in vitro and in vivo models [ 25 , 26 , 27 , 28 ]. Data collected in-laboratory has made significant contribution to understanding the pathomechanism of human diseases from molecular to organismal levels in search of therapeutic targets [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ]. Here, we highlight clinical studies of common pathogenic factors in migraine and NP with reference to preclinical data to explore potential therapeutic targets and clarify the current missing data for it to be complemented in the near future, in search of innovative pain management in migraine and NP.…”

Section: Introductionmentioning

confidence: 99%

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Tajti

Delia

Csáti

et al. 2023

IJMS

View full text Add to dashboard Cite

Migraine and neuropathic pain (NP) are both painful, disabling, chronic conditions which exhibit some symptom similarities and are thus considered to share a common etiology. The calcitonin gene-related peptide (CGRP) has gained credit as a target for migraine management; nevertheless, the efficacy and the applicability of CGRP modifiers warrant the search for more effective therapeutic targets for pain management. This scoping review focuses on human studies of common pathogenic factors in migraine and NP, with reference to available preclinical evidence to explore potential novel therapeutic targets. CGRP inhibitors and monoclonal antibodies alleviate inflammation in the meninges; targeting transient receptor potential (TRP) ion channels may help prevent the release of nociceptive substances, and modifying the endocannabinoid system may open a path toward discovery of novel analgesics. There may exist a potential target in the tryptophan-kynurenine (KYN) metabolic system, which is closely linked to glutamate-induced hyperexcitability; alleviating neuroinflammation may complement a pain-relieving armamentarium, and modifying microglial excitation, which is observed in both conditions, may be a possible approach. Those are several potential analgesic targets which deserve to be explored in search of novel analgesics; however, much evidence remains missing. This review highlights the need for more studies on CGRP modifiers for subtypes, the discovery of TRP and endocannabinoid modulators, knowledge of the status of KYN metabolites, the consensus on cytokines and sampling, and biomarkers for microglial function, in search of innovative pain management methods for migraine and NP.

show abstract

Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors

Cited by 7 publications

References 72 publications

Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy

Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy

Metabolomics Identifies and Validates Serum Androstenedione as Novel Biomarker for Diagnosing Primary Angle Closure Glaucoma and Predicting the Visual Field Progression

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

Contact Info

Product

Resources

About